Antiviral Activity from Medicinal Mushrooms and their Active Constituents

• US 20160000754A1
• Filed: 09/14/2015
• Published: 01/07/2016
• Est. Priority Date: 01/06/2004
• Status: Active Grant

• Current Assignee: Turtle Bear Holdings LLC
• Original Assignee: Paul Edward Stamets
• Inventors: Stamets, Paul Edward
• Granted Patent: US 9,931,316 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/12 Ketones
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61K 31/37 Coumarins, e.g. psoralen
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 36/06 Fungi, e.g. yeasts
• CPC Class Codes: A61K 36/07 Basidiomycota, e.g. Cryptococcus
• CPC Class Codes: A61K 36/074 Ganoderma

Abstract

Compounds having unique antiviral properties found in mushroom mycelium and their analogs are extracted, concentrated, isolated or manufactured to create compositions useful in preventing the spread and proliferation of various viruses afflicting animals, particularly viruses harming humans, pigs, birds, bats and bees. Such compounds and compositions can be used individually or in combination with known medicines or natural products to improve health.

Claims

1. A method for preventing a pathogenic virus infection comprising:

administering a daily dose of a composition to a person wishing to prevent the pathogenic virus infection, wherein the composition is selected from the group consisting of ethyl 7-chloro-2-oxo-4-phenyl-2H-chromen-3-carboxylate, vanillic acid, hispolon, quercetin hydrate, rutin hydrate, syringic acid, trans-cinnamic acid, trans-ferulic acid and salts of vanillic acid, syringic acid, trans-cinnamic acid and trans-ferulic acid, wherein the composition has an antiviral effect and wherein the pathogenic virus is selected from the group consisting of varicella zoster virus, Epstein-Barr virus, herpes simplex I and II viruses, human papillomavirus (HPV), influenza viruses, hepatitis viruses, poliovirus and norovirus.

2. The method of claim 1 wherein the antiviral effect has a selectivity index (5150=CC₅₀/EC₅₀) against the pathogenic virus SI₅₀≧

5.

3. The method of claim 1 wherein the antiviral effect has a selectivity index (SI₅₀=CC₅₀/EC₅₀) against the pathogenic virus SI₅₀≧

10.

4. The method of claim 1 wherein the antiviral effect has a selectivity index (SI₅₀=CC₅₀/EC₅₀) against the pathogenic virus SI₅₀≧

100.

5. The method of claim 1 wherein the daily dose is about 100 to 200 mg per day.

6. The method of claim 1 wherein the daily dose is about 200 mg per day.

7. The method of claim 1 wherein hispolon has an antiviral effect Selectivity Index 50 (SI₅₀)≧

5 against the Epstein-Barr virus, wherein hispolon and ethyl 7-chloro-2-oxo-4-phenyl-2H-chromen-3-carboxylate have an antiviral effect Selectivity Index 50 (SI₅₀)≧

10 against the norovirus, wherein quercetin hydrate, rutin hydrate, syringic acid, trans-cinnamic acid and trans-ferulic acid have an antiviral effect Selectivity Index 50 (SI₅₀)≧

10 against the human papillomavirus (HPV), wherein chrysin has an antiviral effect Selectivity Index 50 (SI₅₀)≧

10 against the poliovirus, wherein rutin hydrate, trans-cinnamic acid and trans-ferulic acid have an antiviral effect Selectivity Index 50 (SI₅₀)≧

100 against the human papillomavirus (HPV) and wherein vanillic acid has an antiviral effect Selectivity Index 50 (SI₅₀)≧

100 against the varicella zoster virus.

8. The method of claim 1 wherein the composition additionally has an antibacterial effect.

9. A method for treating a pathogenic virus infection comprising:

administering a therapeutically effective amount of a composition to a patient suffering from the pathogenic virus infection, wherein the composition is selected from the group consisting of ethyl 7-chloro-2-oxo-4-phenyl-2H-chromen-3-carboxylate, vanillic acid, hispolon, quercetin hydrate, rutin hydrate, syringic acid, trans-cinnamic acid, trans-ferulic acid and salts of vanillic acid, syringic acid, trans-cinnamic acid and trans-ferulic acid, wherein the composition has an antiviral effect against the pathogenic virus and wherein the pathogenic virus is selected from the group consisting of varicella zoster virus, Epstein-Barr virus, herpes simplex I and II viruses, human Papillomavirus (HPV), influenza viruses, hepatitis viruses, poliovirus and norovirus.

10. The method of claim 9 wherein hispolon has an antiviral effect Selectivity Index 50 (SI₅₀)≧

5 against the Epstein-Barr virus, wherein hispolon and ethyl 7-chloro-2-oxo-4-phenyl-2H-chromen-3-carboxylate have an antiviral effect Selectivity Index 50 (SI₅₀)≧

10 against the norovirus, wherein quercetin hydrate, rutin hydrate, syringic acid, trans-cinnamic acid and trans-ferulic acid have an antiviral effect Selectivity Index 50 (SI₅₀)≧

10 against the human papillomavirus (HPV), wherein chrysin has an antiviral effect Selectivity Index 50 (SI₅₀)≧

10 against the poliovirus, wherein rutin hydrate, trans-cinnamic acid and trans-ferulic acid have an antiviral effect Selectivity Index 50 (SI₅₀)≧

100 against the human papillomavirus (HPV) and wherein vanillic acid has an antiviral effect Selectivity Index 50 (SI₅₀)≧

100 against the varicella zoster virus.

11. The method of claim 9 wherein the antiviral effect has a selectivity index (SI₅₀=CC₅₀/EC₅₀) against the pathogenic virus SI₅₀≧

5.

12. The method of claim 9 wherein the antiviral effect has a selectivity index (SI₅₀=CC₅₀/EC₅₀) against the pathogenic virus SI₅₀≧

10.

13. The method of claim 9 wherein the antiviral effect has a selectivity index (SI₅₀=CC₅₀/EC₅₀) against the pathogenic virus SI₅₀≧

100.

14. The method of claim 9 wherein the composition additionally has an antibacterial effect.

15. A method for treating a pathogenic virus infection comprising:

administering a daily dose of a composition to a patient suffering from the pathogenic virus infection for a period of time from 10 to 60 days, wherein the daily dose comprises about 0.001 to 2 grams of the composition, wherein the composition is selected from the group consisting of ethyl 7-chloro-2-oxo-4-phenyl-2H-chromen-3-carboxylate, vanillic acid, hispolon, quercetin hydrate, rutin hydrate, syringic acid, trans-cinnamic acid, trans-ferulic acid and salts of vanillic acid, syringic acid, trans-cinnamic acid and trans-ferulic acid, wherein the composition has an antiviral effect against the pathogenic virus, and wherein the pathogenic virus is selected from the group consisting of varicella zoster virus, Epstein-Barr virus, herpes simplex I and II viruses, human Papillomavirus (HPV), influenza viruses, hepatitis viruses, poliovirus and norovirus.

16. The method of claim 15 wherein the daily dose is about 0.1 to 1.5 grams per day.

17. The method of claim 15 wherein the daily dose is about 0.25 to 1.4 grams per day.

18. The method of claim 15 wherein the daily dose is about 1,000 mg per day.

19. The method of claim 15 wherein hispolon has an antiviral effect Selectivity Index 50 (SI₅₀)≧

5 against the Epstein-Barr virus, wherein hispolon and ethyl 7-chloro-2-oxo-4-phenyl-2H-chromen-3-carboxylate have an antiviral effect Selectivity Index 50 (SI₅₀)≧

10 against the norovirus, wherein quercetin hydrate, rutin hydrate, syringic acid, trans-cinnamic acid and trans-ferulic acid have an antiviral effect Selectivity Index 50 (SI₅₀)≧

10 against the human papillomavirus (HPV), wherein chrysin has an antiviral effect Selectivity Index 50 (SI₅₀)≧

10 against the poliovirus, wherein rutin hydrate, trans-cinnamic acid and trans-ferulic acid have an antiviral effect Selectivity Index 50 (SI₅₀)≧

100 against the human papillomavirus (HPV) and wherein vanillic acid has an antiviral effect Selectivity Index 50 (SI₅₀)≧

100 against the varicella zoster virus.

20. The method of claim 15 wherein the effect has a selectivity index (SI₅₀=CC₅₀/EC₅₀) against the pathogenic virus SI₅₀≧

5.

21. The method of claim 15 wherein the antiviral effect has a selectivity index (SI₅₀=CC₅₀/EC₅₀) against the pathogenic virus SI₅₀≧

10.

22. The method of claim 15 wherein the antiviral effect has a selectivity index (SI₅₀=CC₅₀/EC₅₀) against the pathogenic virus SI₅₀≧

100.

23. The method of claim 15 wherein the composition additionally has an antibacterial effect.

24. A method for manufacturing a dosing form for treating, ameliorating, mitigating, alleviating, reducing and curing a virus infection comprising:

formulating a composition into a dosage form selected from the group consisting of sprays, capsules, tablets, elixirs, emulsions, lozenges, suspensions, syrups, pills, lotions, epidermal patches, suppositories, inhalers and injectables, wherein the composition is selected from the group consisting of ethyl 7-chloro-2-oxo-4-phenyl-2H-chromen-3-carboxylate, vanillic acid, hispolon, quercetin hydrate, rutin hydrate, syringic acid, trans-cinnamic acid, trans-ferulic acid and salts of vanillic acid, syringic acid, trans-cinnamic acid and trans-ferulic acid, and wherein the composition has an antiviral effect against a pathogenic virus selected from the group consisting of varicella zoster virus, Epstein-Barr virus, herpes simplex I and II viruses, human papillomavirus (HPV), poliovirus, and norovirus.

25. The method of claim 24 wherein the antiviral effect has a selectivity index (SI₅₀=CC₅₀/EC₅₀) against the virus SI₅₀≧

5.

26. The method of claim 24 wherein the antiviral effect has a selectivity index (SI₅₀=CC₅₀/EC₅₀) against the virus SI₅₀≧

10.

27. The method of claim 24 wherein the antiviral effect has a selectivity index (SI₅₀=CC₅₀/EC₅₀) against the virus SI₅₀≧

100.

28. The method of claim 24 wherein hispolon has an antiviral effect Selectivity Index 50 (SI₅₀)≧

5 against the Epstein-Barr virus, wherein hispolon and ethyl 7-chloro-2-oxo-4-phenyl-2H-chromen-3-carboxylate have an antiviral effect Selectivity Index 50 (SI₅₀)≧

10 against the norovirus, wherein quercetin hydrate, rutin hydrate, syringic acid, trans-cinnamic acid and trans-ferulic acid have an antiviral effect Selectivity Index 50 (SI₅₀)≧

10 against the human papillomavirus (HPV), wherein chrysin has an antiviral effect Selectivity Index 50 (SI₅₀)≧

10 against the poliovirus, wherein rutin hydrate, trans-cinnamic acid and trans-ferulic acid have an antiviral effect Selectivity Index 50 (SI₅₀)≧

100 against the human papillomavirus (HPV) and wherein vanillic acid has an antiviral effect Selectivity Index 50 (SI₅₀)≧

100 against the varicella zoster virus.

29. The method of claim 24 wherein the composition additionally has an antibacterial effect.

30. The method of claim 24 wherein the dosing form additionally comprises CBD (cannabidiol).